BURBANK, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medolife Rx, Inc. (“Medolife” or the “Company”), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today two clarifications to its press release, dated April 13, 2021:
1. The Company has conducted extensive preclinical studies on Escozine® as a therapeutic for both COVID-19 and multiple forms of cancer in the US and globally.
2. The Company has conducted preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States, Dominican Republic and Mexico first through the following instruments:
a. The Pharmaceutical...